The invention relates to compounds of the following formula (I). In these compounds, R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each independently a substituted or unsubstituted cyclitol with a ring comprising six carbon atoms, or hydrogen, substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, alkyloxycarbonyl, or alkylaminocarbonyl. At least two of R.sub.1, R.sub.2, R.sub.3 and R.sub.4 comprise the substituted or unsubstituted cyclitol. The linker can be any one of the following: --(CH.sub.2).sub.w--, --(CH.sub.2).sub.x--C.sub.6H.sub.4--(CH.sub.2).sub.x--, --(CH.sub.2).sub.y--NR.sub.5--(CH.sub.2).sub.y--, and --(CH.sub.2).sub.z--HCR.sub.6--(CH.sub.2).sub.z--; wherein: w, x, y and z are independently an integer having a value of 0 10; R.sub.5 is a substituted or unsubstituted cyclitol with a ring comprising six carbon atoms; and, R.sub.6 is --OH, --OSO.sub.3Na, --OSO.sub.3Na substituted with alkyl, cycloalkyl or aryl, or substituted or unsubstituted alkyl, cycloalkyl or aryl. The compounds can also include substituted or unsubstituted cyclitol carbamides with the linker bond at the carbamide nitrogen. In other embodiments, the invention provides pharmaceutical compositions which include the compounds, and use of the compounds in the prevention or treatment in a mammalian subject of a disorder resulting from angiogenesis, metastasis, inflammation and/or coagulation/thrombosis ##STR00001##